Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Ocrelizumab (Ocrevus) and Ofatumumab (Kesimpta) — clinical data, side effects, and patient experiences.
Ocrevus · Anti-CD20 Monoclonal Antibody
How it works
Humanized anti-CD20 monoclonal antibody that depletes B cells via antibody-dependent cellular cytolysis and complement-mediated lysis.
Approved for
Kesimpta · Anti-CD20 Monoclonal Antibody
How it works
Fully human anti-CD20 monoclonal antibody self-administered subcutaneously that depletes B cells.
Approved for
Estimated frequency (%) based on clinical trial data
No specific warnings
No head-to-head clinical studies found for Ocrelizumab vs Ofatumumab.
Both Ocrelizumab and Ofatumumab belong to the Anti-CD20 Monoclonal Antibody class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. Ocrelizumab is administered via Intravenous, whereas Ofatumumab uses Oral. Route of administration can affect onset of action and patient adherence.
Both medications are approved for Relapsing Multiple Sclerosis. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Ocrelizumab carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.